FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

vvaoriington,	D.O. 200-0	

OMB APPROVAL

OMB Number:	3235-0287					
Estimated average burden						
hours per response:	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* WILSON TROY EDWARD					2. Issuer Name <b>and</b> Ticker or Trading Symbol Kura Oncology, Inc. [ KURA ]				(Ch	S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner					
(Last) (First) (Middle) C/O KURA ONCOLOGY, INC. 3033 SCIENCE PARK ROAD, SUITE 220				3. Date of Earliest Transaction (Month/Day/Year) 01/22/2019				X Officer below)	Officer (give title Othe						
(Street) SAN DII		A tate)	92121 (Zip)	4.	If Ame	endment, [	Oate o	f Original Fil	ed (Month/D	ay/Year)	Line	e) <mark>X</mark> Form fil	oint/Group Filir ed by One Re ed by More tha	porting Person	
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transa Date (Month/D			ransaction	Execution Date,		3. Transact Code (Ins	4. Secu	rities Acqui		5. Amour	s For	orm: Direct D) or Indirect	7. Nature of Indirect Beneficial Ownership		
						Code	Amoun	(A) (D)	or Price	Reported Transacti (Instr. 3 a	on(s)		Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)			Transa Code (	nsaction Derivative E		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Option to purchase common stock	\$15.47	01/22/2019		A		220,000		(1)	01/21/2029	Common Stock	220,000	\$0.00	220,000	D	

## **Explanation of Responses:**

 $1. \ This \ option \ vests \ in \ 48 \ equal \ monthly \ installments \ commencing \ on \ the \ grant \ date.$ 

## Remarks:

Annette North, Attorney-in-fact 01/24/2019 for Troy E. Wilson

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.